About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Chicago | 9,860 Studies Near You | Clareo Health

Clinical Trials LocationsChicago

Clinical Trials in Chicago

Discover 9,860 clinical trials near Chicago, Illinois. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2621-2640 of 9,860 trials

Active Not RecruitingNA2.2 miles

Improving Sleep in Gynecologic Cancer Survivors

NCT05044975

This purpose of this study is to learn about how to provide treatment to gynecologic cancer survivors who have difficulty sleeping.

Sleep DisturbanceGynecologic Cancer

University of Arizona95 participantsStarted Oct 2021

Tucson, Arizona, United States • Chicago, Illinois, United States

Active Not RecruitingPhase 32.2 miles

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

Ectonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of Infancy

Inozyme Pharma27 participantsStarted Nov 2023

Aurora, Colorado, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +12 more locations

Find Trials by Condition in Chicago

Breast Cancerin Chicago Lung Cancerin Chicago Prostate Cancerin Chicago Colorectal Cancerin Chicago Melanomain Chicago Leukemiain Chicago Lymphomain Chicago Pancreatic Cancerin Chicago Ovarian Cancerin Chicago Brain Cancerin Chicago Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 32.2 miles

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT02076009

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Multiple Myeloma

Janssen Research & Development, LLC569 participantsStarted Jul 2014

Little Rock, Arkansas, United States • Gainesville, Florida, United States • West Palm Beach, Florida, United States +142 more locations

RECRUITING2.2 miles

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT06950788

The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation. The question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant? Participants will be asked to periodically participate in wearing a continuous glucose monitor and wrist actigraph and obtain an oral glucose tolerance test both before and after liver transplant.

Cirrhosis, LiverDiabetes Mellitus RiskTransplant; Failure, Liver+1 more

University of Chicago60 participantsStarted Mar 2024

Chicago, Illinois, United States

COMPLETEDPhase 12.2 miles

Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma

NCT03011671

This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)). During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will be started on the day of TMZ initiation and continued for a total of 21 days.

Malignant Glioma of Brain

University of Chicago10 participantsStarted Oct 2018

Chicago, Illinois, United States

COMPLETEDPhase 22.2 miles

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

NCT02473289

The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50 milligram (mg) subcutaneous (SC) injection at Day 1, Day 28 and Day 56 during the 12- week double-blind treatment period) is compared to adjunctive placebo based on the change from baseline to 12-week endpoint in depressive symptoms as measured by the total score on the Hamilton Depression Rating Scale (HDRS), in participants diagnosed with Major Depressive Disorder (MDD) who have had a suboptimal response to the current standard oral antidepressant therapy and have a screening high sensitivity C-Reactive Protein (hsCRP) \>=0.300 milligram per deciliters (mg/dL) (International System of Units (SI) 3.00 mg/L). A cohort of subjects with hsCRP \<0.300 milligram per deciliter will also be enrolled to allow a better understanding of the relationship between CRP and clinical changes.

Depressive Disorder, Major

Janssen Research & Development, LLC193 participantsStarted Jul 2015

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Bellflower, California, United States +43 more locations

Active Not Recruiting2.2 miles

Quality of Life in Pre and Post Renal Transplant in Hispanic and Non-Hispanic Recipients

NCT00856895

The purpose of study is to measure the quality of life (QOL) of patients pre and post kidney transplant by asking them to fill out a survey. Patients will be asked to fill out the survey before transplant, 3 months post-transplant, and 1 year post-transplant to see how the transplant relates to any progression in quality of life. QOL will be assessed to correlate the quality of life and aspects of renal function prospectively at pre and post-transplant across all ethnicities and variances of donor types at three time points. First, there will be a prospective assessment of QOL in the Hispanic and Non-Hispanic kidney recipients before and after transplant at NMH and Colombiana de Transplantes. Second, there will be an assessment of the Hispanic kidney patients that have been transplanted over the last 10 years at NMH and Colombiana de Transplantes, in a cross-sectional fashion. Third, there will be a comparison and determination of the differences in QOL in the Hispanic population before and after the Hispanic Transplant program was initiated in November 2006. Lastly, there will be an assessment of the social impact of the services that NMH's Hispanic Transplant Program provides to patients. The questionnaires completed by the subjects at NMH will be the same questionnaires completed by the subjects in Colombia. The data obtained from Colombiana de Transplantes will be de-identified data and provided to us via a password protected excel file delivered to the principal investigator electronically.

Transplant; Failure, Kidney

Northwestern University1,200 participantsStarted Oct 2007

Chicago, Illinois, United States

RECRUITING2.2 miles

Chronic Pain in Rheumatoid Arthritis

NCT05038553

The objective is to identify modifiable clinical factors and neurobiological pathways that lead to the development of chronic pain in patients with early rheumatoid arthritis. Participants will undergo quantitative sensory testing, a type of testing that involves assessing response to well-defined, quantifiable painful stimuli, at 0, 3, and 12 months. A subset of participants will also undergo magnetic resonance imaging at 0 and 12 months to assess neuroimaging markers that have previously been shown to be involved in chronic pain.

Arthritis, RheumatoidPain

Northwestern University125 participantsStarted Oct 2021

Denver, Colorado, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +2 more locations

COMPLETED12 miles

Individually-guided Hearing Aid Fitting

NCT03345654

This translational project aims to optimize the fitting of hearing aids by development and clinical validation of a toolset that guides signal processing choice based on the individual auditory and cognitive abilities of the patient.

Northwestern University42 participantsStarted Sep 2023

Evanston, Illinois, United States

RECRUITINGNA80 miles

Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors

NCT05373017

This study will evaluate the usefulness of the Urgent and Emergency Surgery (UES) Delirium Recovery Model. It is hypothesized that the cognitive, physical and psychological recovery of older UES delirium survivors will be improved through the use of the DANE Recovery Model. Participants can expect to be on the study for 18 months.

University of Wisconsin, Madison528 participantsStarted Feb 2023

Rockford, Illinois, United States • Indianapolis, Indiana, United States • Madison, Wisconsin, United States +3 more locations

RECRUITINGNA125 miles

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

NCT04503395

The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).

Aortic Aneurysm, Abdominal

FCRE (Foundation for Cardiovascular Research and Education)204 participantsStarted May 2021

La Jolla, California, United States • Stanford, California, United States • Gainesville, Florida, United States +29 more locations

RECRUITINGNA125 miles

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

NCT02235857

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia). Although the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.

Focal Segmental Glomerulosclerosis

Kaneka Medical America LLC35 participantsStarted May 2015

Loma Linda, California, United States • Los Angeles, California, United States • Wilmington, Delaware, United States +9 more locations

TERMINATEDPhase 1237 miles

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05757492

This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous \[NSCLC-NS\] and Hepatocellular carcinoma \[HCC\])

Advanced Solid TumorNon-Small Cell Lung CancerHepatocellular Carcinoma

Coherus Oncology, Inc.22 participantsStarted Apr 2023

Orlando, Florida, United States • Detroit, Michigan, United States • Reno, Nevada, United States +1 more locations

RECRUITINGNA276 miles

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06455475

This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers

Diabetic Foot Ulcer

Capsicure, LLC150 participantsStarted Oct 2024

Athens, Alabama, United States • Encino, California, United States • Hollywood, Florida, United States +8 more locations

COMPLETEDPhase 2414 miles

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

NCT04129164

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Sjögren's Syndrome

Amgen183 participantsStarted Dec 2019

Fullerton, California, United States • Upland, California, United States • Lawrenceville, Georgia, United States +59 more locations

COMPLETEDPhase 4432 miles

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218

The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (\>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment. A primary objective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study.

Rheumatoid ArthritisPsoriatic ArthritisSpondylarthritis

Jeffrey Curtis841 participantsStarted Nov 2021

Birmingham, Alabama, United States • Hoover, Alabama, United States • Hoover, Alabama, United States +5 more locations

RECRUITINGPhase 1/2805 miles

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

NCT06942572

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week period post treatment after a single administration of SB-007.

Stargardt DiseaseStargardt Macular DegenerationStargardt Macular Dystrophy

Splice Bio57 participantsStarted Feb 2025

Aurora, Colorado, United States • Miami, Florida, United States • Boston, Massachusetts, United States +2 more locations

RECRUITINGNA811 miles

Promoting Early Intervention Timing and Attention to Language

NCT05853861

The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months. Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (incorporates JASPER intervention and Babble Bootcamp) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.

University of California, Los Angeles140 participantsStarted Nov 2024

Los Angeles, California, United States • Worcester, Massachusetts, United States

COMPLETEDNA814 miles

A Digital Intervention to Improve Physical Activity and Sleep Behaviors in Youth With Psychiatric Diagnoses

NCT05505578

The goal of "GamerFit" is to test the delivery of a theory-based mHealth app that utilizes social support, exergaming, and telehealth coaching to improve PA levels, sleep, and psychiatric symptoms among youth participants (ages 13-17 y) with PD. In order to aid future intervention optimization, up to 65 participants with at least one PD will be randomized, with 30-35 using the GamerFit app with weekly telehealth coaching sessions and 30-35 using a commercial healthy habits app as a comparator group

Psychiatric Diagnosis

Pennington Biomedical Research Center62 participantsStarted Jan 2023

Baton Rouge, Louisiana, United States • North Andover, Massachusetts, United States

RECRUITINGNA916 miles

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

NCT06098482

The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.

Cochlear46 participantsStarted Feb 2024

Lone Tree, Colorado, United States • Melbourne, Victoria, Australia • Antwerp, Antwerp, Belgium +1 more locations

PreviousPage 132 of 493Next

in Chicago

Heart Diseasein Chicago